Introduction
Among the various signaling molecules activated by insulin, a number of in vitro studies indicate that the class I A phosphoinositide 3-kinase (PI 3-K), which consists of a 110-kDa catalytic subunit and an Src homology 2 domain-containing regulatory subunit, plays a key role in the metabolic actions of this hormone (1, 2) . Wortmannin and LY 294002, inhibitors of both class I A and class I B PI 3-Ks, thus prevent a variety of biological effects of insulin (1, 2) . Ectopic expression of a dominant negative form of class I A PI 3-K has also revealed the importance of this enzyme in metabolic control by insulin (3) (4) (5) (6) . Furthermore, analysis of human subjects and animal models has indicated the existence of a correlation between impaired activation of PI 3-K in target tissues of insulin and insulin resistance in vivo (7) (8) (9) . These various observations suggest that a disturbance of signaling mediated by this lipid kinase might contribute to the development of insulin resistance and, consequently, to the pathogenesis of type 2 diabetes.
Targeted gene disruption is also an important tool for investigating the role of specific proteins in vivo. Genes encoding three different isoforms (p110α, p110β, and p110γ) of the catalytic subunit of class I A PI 3-K have been identified (2) . Disruption of the p110α gene, which is widely expressed among tissues, resulted in embryonic death in mice (10) . Three genes encoding regulatory subunits (p85α, p85β, and p55γ) of class I A PI 3-K have been identified, and that for p85α also gives rise to two smaller variant proteins known as p55α and p50α (or AS53) (2) . The metabolic phenotypes of mice lacking the p85α gene (11, 12) or the p85β gene (13) , as well as of those selectively deficient in the p85α protein (14) , have been described; unexpectedly, all these animals exhibited lower blood glucose concentrations and increased insulin sensitivity compared with controls. Although the mechanism responsible for these phenotypes remains unclear, the insulin-induced association of PI 3-K activity with tyrosine-phosphorylated proteins or with insulin receptor substrate (IRS) proteins, shown to be important for insulin action by in vitro studies (1, 2) , was only partially (11, 14) or minimally (12, 13) attenuated in the targeted mice. The metabolic impact of prevention of the insulin-dependent activation of PI 3-K in vivo has thus not been elucidated to date.
Given that both humans with diabetes and many animal models of insulin resistance manifest defects in insulin responses in multiple tissues, it has been difficult to determine which impairment in which tissue is primarily responsible for a particular metabolic disturbance. Although several mouse models have been established that lack a specific protein in a specific tissue, these models have still exhibited abnormalities in multiple organs, probably due to secondary effects of chronic metabolic alterations (15, 16) .
We have now investigated the metabolic impact of inhibition of hepatic PI 3-K signaling in vivo by systemic infusion of an adenoviral vector encoding a dominant negative mutant of class I A PI 3-K in mice. This procedure resulted in liver-specific expression of the mutant protein and in almost complete inhibition of the insulininduced increase in hepatic PI 3-K activity within 3 days, a time course consistent with minimization of secondary effects due to chronic metabolic alterations. The acute inhibition of hepatic PI 3-K signaling resulted in several abnormalities in glucose and lipid metabolism.
Methods
Animals, adenoviruses, and statistical analysis. An adenoviral vector (AxCA∆p85) encoding a dominant negative mutant of class I A PI 3-K, consisting of bovine p85α lacking the binding site for the catalytic subunit, was described previously (3) , and an adenovirus encoding β-galactosidase (AxCALacZ) was kindly provided by I. Saito (University of Tokyo, Tokyo, Japan). Male BALB/c mice (8-10 weeks of age) were injected, via the tail vein, with adenoviral vectors at a dose of 5 × 10 8 plaqueforming units (dissolved in 150 µl of saline) per animal or with 150 µl of saline. Experiments were performed 3 days after adenovirus injection unless otherwise indicated. Blood glucose and plasma insulin concentrations were determined with a GLUTEST PRO (Sanwa Kagaku Kenkyusho Co., Nagoya, Japan) and a mouse insulin ELISA kit (Seikagaku Co. Tokyo, Japan), respectively. For assaying time course of plasma insulin concentration in DNPI3K and LacZ mice, a Mouse Insulin ELISA KIT (Ultra-sensitivity) was used (Shibayagi Co., Shibukawa, Gunma, Japan). In those experiments, the plasma concentration of insulin in mice that had not been injected with adenovirus was below the limit of detection (39 pg/ml) of this ELISA kit. Other serum components were assayed with an autoanalyzer (model 7170; Hitachi High-Technologies Co., Tokyo, Japan). Statistical analysis was performed with Student t tests.
Immunoblot analysis and assay of PI 3-K activity. Mice deprived of food for 16 hours were injected with human regular insulin (5 U/kg of body mass) or saline via the tail vein. After 2 minutes, the animals were sacrificed, and the liver, hindlimb muscle, and epididymal fat were removed. Total homogenates were prepared from each tissue and subjected to immunoblot analysis (∼200 µg of protein) or immunoprecipitation (∼5 mg of protein). An mAb (G12) that recognizes bovine p85, but not rodent p85, was described previously (17) . Polyclonal antibodies to p85, to IRS-1, to IRS-2, to phosphotyrosine (4G10), or to Akt1 were obtained from Upstate Biotechnology Inc. (Lake Placid, New York, USA); those to the β subunit of the insulin receptor (IR) or to glycogen synthase kinase-3β (GSK3β) were from Transduction Laboratories (Lexington, Kentucky, USA); and those specific for phosphorylated forms of Akt (phosphoSer 473 ) or GSK3 (phospho-Ser 9 ) were from Cell Signaling Technology (Beverly, Massachusetts, USA). PI 3-K activity in immunoprecipitates was assayed as described (3) .
Oral glucose tolerance, insulin tolerance, and pyruvate challenge tests. For the oral glucose tolerance test, mice deprived of food for 16 hours were loaded orally with glucose (2 g/kg) and killed 120 minutes later. The liver was removed and subjected to various assays. The glycogen (18) and glucose 6-phosphate (19) contents and glycogen synthase activity (20) were determined as described. For the insulin tolerance test, nonfasted mice were injected intraperitoneally with human regular insulin (0.75 U/kg). For the pyruvate challenge test, mice deprived of food for 16 hours were injected intraperitoneally with pyruvate dissolved in saline (2 g/kg); where indicated, 3-mercaptopicolinic acid (3-MPA; 30 mg/kg), an inhibitor of gluconeogenesis (21, 22) , was administered orally 30 minutes before the test. The 3-MPA was synthesized as described (23) .
Northern blot and real-time quantitative PCR analyses. For determination of the abundance of glucokinase, glucose-6-phosphatase, phosphoenolpyruvate carboxykinase (PEPCK), and GLUT2 mRNAs, total RNA (∼15 µg) extracted from the liver of mice that had been deprived of food for 16 hours was subjected to Northern blot analysis with 32 P-labeled probes. Given that the hybridization signal intensity for sterol regulatory element-binding protein-1 (SREBP-1) mRNA from food-deprived mice was too weak for quantitative analysis, this mRNA was analyzed with total RNA prepared from nonfasted mice. Probes for glucokinase (24) , SREBP-1 (25) , PEPCK (26) , and glucose-6-phosphatase (27) mRNAs were kindly provided by T. Noguchi (Nagoya University, Nagoya, Japan), H. Shimano (University of Tokyo), D.K. Granner (Vanderbilt University Medical Center, Nashville, Tennessee, USA), and H. Nakajima (Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan), respectively, and that for rat GLUT2 mRNA was synthesized by PCR. Autoradiograms of Northern blots were visualized with a Fuji BAS2000 image analyzer (FujiFilm Co., Tokyo, Japan). For real-time quantitative PCR analysis, cDNA was synthesized from total RNA that had been extracted from the liver of mice deprived of food for 16 hours. The cDNA was then analyzed in a Sequence Detector (model 7900; PE Applied Biosystems) with specific primers and SYBR Green PCR Master (Perkin Elmer Life Sciences Inc., Boston, Massachusetts, USA). The relative abundance of mRNAs was calculated by the comparative cycle of threshold (C T ) method with 36B4 mRNA as the
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Expression of a dominant negative mutant of PI 3-K (∆p85) in mice by adenovirus-mediated gene transfer.
Systemic infusion of adenoviral vectors has been shown to result in liver-specific expression of exogenous genes (28, 29) . We therefore attempted to disrupt insulin-induced activation of PI 3-K in liver by an adenoviral vector (AxCA∆p85) encoding a dominant negative mutant of PI 3-K (3). This mutant protein, which corresponds to bovine p85α without the binding site for the catalytic subunit, competes with endogenous regulatory subunits of class I A PI 3-K in binding to tyrosine-phosphorylated proteins (17) and, consequently, prevents intracellular signaling transmitted through this lipid kinase (3) (4) (5) (6) . Mice were injected with AxCA∆p85 via the tail vein, and expression of ∆p85 in liver was examined at various times thereafter by immunoblot analysis with an mAb that recognizes bovine, but not rodent, p85. The ∆p85 protein was detected within 1 day of vector injection; its abundance was maximal at 3-5 days and decreased thereafter, returning to undetectable levels within 11 days (Figure 1a ). Immunoblot analysis of various other tissues of the injected mice failed to detect ∆p85 ( Figure 1b ). The amount of total (bovine and mouse) p85 protein in the liver of mice injected with AxCA∆p85 (DNPI3K mice) was at least five to six times that present in the liver of control mice injected with an adenoviral vector (AxCALacZ) encoding β-galactosidase ( Figure 1c ). The time course and tissue specificity of β-galactosidase expression in mice injected with AxCALacZ (LacZ mice) were similar to those of ∆p85 expression in DNPI3K mice (data not shown). We therefore performed experiments 3 days after adenovirus injection.
We next evaluated the effects of adenovirus infection on metabolic parameters. Mice were injected with AxCALacZ or saline, and various metabolic parameters were measured at 3 days after the injection in the fasted state. There was no significant difference in plasma insulin and serum concentrations of triglycerides, cholesterol, and albumin (Table 1) . Moreover, blood glucose concentrations in the fasted state and after oral glucose intake did not significantly differ between LacZ mice and saline-injected mice. Although the serum levels of aspartate aminotransferase (AST) (36 ± 3.9 IU/l vs. 37.5 ± 5.1 IU/l) did not significantly differ between LacZ mice and saline-injected mice, those of alanine aminotransferase (ALT) were higher in LacZ mice than in saline-injected mice (149 ± 28 vs. 82.2 ± 7.3 IU/l; P < 0.05), probably due to the effect of adenovirus infection (data are means ± SEM of values from four LacZ and five saline mice). We therefore performed most experiments with the use of LacZ mice as control hereafter. The serum levels of AST and ALT in DNPI3K mice (221 ± 33 IU/l and 80 ± 2.0, respectively) were higher than in LacZ mice (data are means ± SEM of values from four mice; P < 0.01). Histological analysis revealed no signs of acute hepatic damage, such as infiltration of mononuclear cells, hepatocyte necrosis, or biliary congestion, in LacZ mice and DNPI3K mice (data not shown). The mass of the liver of DNPI3K
Figure 1
Expression of ∆p85 in the liver of mice injected with an adenoviral vector. (a) Time course of the expression of ∆p85 in the liver. The liver was removed from mice at the indicated times after injection with AxCA∆p85, or from uninjected animals (day 0), and was subjected to immunoblot analysis (IB) with an mAb specific for bovine p85. (b) Total homogenates of the indicated tissues obtained from mice 3 days after injection with AxCA∆p85 were subjected to immunoblot analysis with the mAb to bovine p85. (c) Liver homogenates prepared from mice 3 days after injection with AxCALacZ or AxCA∆p85 were subjected to immunoblot analysis with polyclonal antibodies that recognize both rodent and bovine p85. Data in a and b are representative of results obtained from three mice; those in c were obtained from four mice for each group. mice was approximately 70% of that of LacZ mice (3.55% ± 0.09% vs. 5.06% ± 0.10% body weight; means ± SEM of values from six mice; P < 0.01).
Effects of ∆p85 on insulin-induced activation of signaling molecules and gene expression in liver. DNPI3K and LacZ mice were deprived of food for 16 hours and then injected with insulin or saline; then the liver was removed and subjected to various assays. Immunoprecipitation and immunoblot analysis revealed no difference in either the abundance of the IR or the extent of insulininduced tyrosine phosphorylation of the IR between the two groups of mice (Figure 2a) . Unexpectedly, the abundance of IRS-1 was reduced by about 60% in DNPI3K mice; however, the extent of tyrosine phosphorylation of IRS-1 in the basal state was higher, and that in the insulin-stimulated state was only slightly lower, in DNPI3K mice than in LacZ mice. The amount of IRS-1 mRNA in the liver, as determined by real-time quantitative PCR analysis, did not differ between DNPI3K mice and LacZ mice (0.091 ± 0.008 vs. 0.083 ± 0.015 U, respectively, relative to the amount of 36B4 mRNA; means ± SEM of values from four mice), suggesting that the reduced abundance of IRS-1 protein in DNPI3K mice was attributable to a posttranscriptional event. Whereas the amount of IRS-2 did not differ between the two groups of mice, the extents of both basal and insulin-induced tyrosine phosphorylation of IRS-2 were increased in DNPI3K mice (Figure 2a) . Although the mechanism responsible for the enhanced
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The tyrosine phosphorylation of IRS proteins in DNPI3K mice is unknown, it is possible that prevention by ∆p85 of negative feedback regulation of IRS phosphorylation may be a contributing factor. The insulin-induced association of PI 3-K activity with either IRS-1 or IRS-2 was almost completely abolished in DNPI3K mice (Figure 2b ), likely as a result of a dominant negative effect of ∆p85. Furthermore, the insulininduced phosphorylation of Akt, a protein kinase that functions downstream of PI 3-K (1, 2), was markedly inhibited in DNPI3K mice (Figure 2d) ; the abundance of Akt did not differ between DNPI3K and LacZ mice. These results thus indicate that almost complete inhibition of the insulin-induced activation of PI 3-K and of downstream effectors was achieved in the liver within 3 days after injection of AxCA∆p85.
Northern blot analysis of total RNA isolated from the liver of DNPI3K and LacZ mice revealed that the abundance of mRNAs for glucokinase and SREBP-1 was reduced whereas that of PEPCK and glucose-6-phosphatase mRNAs was increased in DNPI3K mice (Figure 2c ). These data indicate that PI 3-K signaling contributes to the regulation of these genes in vivo, consistent with results obtained with cultured cells (5, 6, 30, 31 ). In contrast, the amount of GLUT2 mRNA did not differ between the two groups of mice.
Effects of ∆p85 on insulin-induced activation of signaling molecules in skeletal muscle and adipose tissue.
Neither the abundance of the IR nor the extent of insulininduced tyrosine phosphorylation of the IR in skeletal muscle differed between DNPI3K and LacZ mice (Figure 3a) . In addition, no marked differences were apparent in the amounts of IRS-1 or IRS-2, in the extents of basal or insulin-induced tyrosine phosphorylation of IRS-1, or in the insulin-induced association of PI 3-K activity with IRS-1 or IRS-2 between skeletal muscle of DNPI3K mice and that of LacZ mice (Figure 3, a and b) . The insulin-induced phosphorylation of Akt in skeletal muscle was also not impaired in DNPI3K mice (Figure 3c ). Insulin signaling in skeletal muscle thus did not appear to be affected by expression of ∆p85 in the liver.
The mass of epididymal adipose tissue in fasted DNPI3K mice was about 1.5 times that in fasted LacZ mice (1.67% ± 0.04% vs. 1.09% ± 0.07% body weight, P < 0.01), whereas this parameter did not differ significantly between nonfasted DNPI3K and LacZ mice (1.74% ± 0.09% vs. 1.69% ± 0.10% body weight, respectively; all data are means ± SEM of values from six mice). Neither the abundance of the IR, IRS-1, or IRS-2 nor the extents of insulin-induced tyrosine phosphorylation of the IR or IRS-1 in adipose tissue differed substantially between DNPI3K and LacZ mice (Figure 3a) . The extent of insulininduced tyrosine phosphorylation of IRS-2 in both skeletal muscle and adipose tissue was too small for analysis (data not shown). The insulin-induced association of PI 3-K activity with IRS-1 or IRS-2 in adipose tissue was reduced by approximately 40% in DNPI3K mice compared with that apparent in LacZ mice (Figure 3b) . The insulin-induced phosphorylation of Akt in adipose tissue, however, did not differ between the two groups of mice (Figure 3c ). These results indicate that expression of ∆p85 in the liver resulted in impairment of the activation of PI 3-K by insulin in adipose tissue and that the mass of this tissue in the fasted state was greater than that of control animals.
Effects of ∆p85 on metabolic parameters. There was no significant difference in body mass between DNPI3K and LacZ mice (22.8 ± 0.5 vs. 21.8 ± 0.4 g, respectively; means ± SEM of values from eight mice). The fasting blood glucose concentration of DNPI3K mice was only slightly, but significantly, higher than that of LacZ mice (Table  2 ). In the nonfasted state, blood glucose concentrations were similar in both groups of mice. Plasma insulin concentrations of DNPI3K mice in the fasted and fed states were approximately 4 and 1.8 times, respectively, those of LacZ mice, suggesting that the inhibition of insulininduced activation of PI 3-K in the liver resulted in insulin resistance. The serum concentrations of FFAs, cholesterol, triglycerides, and glycerol (a precursor for gluconeogenesis) were significantly lower in DNPI3K mice than in LacZ mice. The serum concentration of lactate, another gluconeogenic substrate, was also lower in DNPI3K mice than in LacZ mice, but the difference was not statistically significant. The serum albumin concentration was reduced by approximately 17% in DNPI3K mice. The abundance of albumin mRNA in the liver was also reduced by more than 60% in DNPI3K mice compared with that in LacZ mice (42.8 ± 8.4 vs. 119.0 ± 13.7 U relative to the amount of 36B4 mRNA; means ± SEM of values from four mice; P < 0.01), consistent with the observation that the expression of albumin is regulated by insulin at the transcriptional level (32) .
The plasma insulin concentration of DNPI3K mice was already higher than that of LacZ mice 1 day after vector injection, was maximal at 3-5 days, and had decreased markedly by 7 days (Figure 4a ). The similarity in kinetics between the plasma insulin concentration and the expression of ∆p85 in the liver suggests that the metabolic changes in DNPI3K mice result from inhibition of insulin-induced PI 3-K signaling in the liver.
Effects of ∆p85 on glucose and insulin tolerance. The blood glucose concentrations of DNPI3K mice were significantly greater than those of LacZ mice after oral glucose intake (Figure 4b ). The marked hyperglycemia of DNPI3K mice persisted even 120 minutes after initiation of the test, when blood glucose concentration had returned to almost basal values in LacZ mice. Plasma insulin concentrations of DNPI3K mice were higher than those of LacZ mice at all times examined after oral glucose intake, although the difference was statistically significant only at 120 minutes ( Figure 4c) ; these results are consistent with the notion that glucose intolerance in DNPI3K mice is attributable to insulin resistance. However, the glucose-lowering effect of exogenously administered insulin was similar in the two groups of mice (Figure 5a ). At 11 days after the injection of the adenoviruses, at which time the abundance of ∆p85 protein had returned to undetectable
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The levels (Figure 1a) , the blood glucose concentrations after oral glucose intake did not differ between DNPI3K and LacZ mice (Figure 4d) . Effects of ∆p85 on glycogen and glucose 6-phosphate accumulation during the glucose tolerance test. Hepatic glycogen content increased by a factor of about 40 within 120 minutes of oral glucose intake in LacZ mice, whereas this effect was reduced by more than 80% in DNPI3K mice (Figure 4e ). The hepatic content of glucose 6-phosphate, an initial metabolite of glucose, in DNPI3K mice was also reduced by 60% and 80% before and after oral intake of glucose, respectively, compared with the corresponding values for LacZ mice (Figure 4f) .
Phosphorylation of Akt and that of GSK3, both of which are thought to contribute to the activation of glycogen synthase (20, 33) , were stimulated in the liver of LacZ mice by glucose intake (Figure 4h ). In contrast, the phosphorylation of both of these kinases in response to oral glucose intake was markedly impaired in the liver of DNPI3K mice. At 11 days after the adenovirus injection, phosphorylation of Akt induced by glucose intake did not differ between DNPI3K and LacZ mice (Figure 4d, inset) . Oral glucose induced an approximately 2.5-fold increase in the activity of glycogen synthase in the liver of LacZ mice (Figure 4g ). The hepatic activity of glycogen synthase in DNPI3K mice before glucose intake was only about 50% of the corresponding value for LacZ mice, and the glucose-induced activation of this enzyme in the liver of DNPI3K mice was also markedly impaired.
Effect of ∆p85 on the pyruvate-induced increase in blood glucose concentration. Finally, we investigated the blood glucose response to administration of pyruvate, a precursor for gluconeogenesis. In LacZ mice, the blood glucose concentration was increased 30 minutes after pyruvate injection and had returned to almost basal levels within 120 minutes (Figure 5b) . In DNPI3K mice, the increase in blood glucose concentration persisted at 120 minutes after pyruvate injection. The pyruvate-induced increase in blood glucose concentration was abolished by prior administration of 3-MPA, an inhibitor of gluconeogenesis (21, 22) , in both groups of mice, suggesting that this effect of pyruvate was dependent on gluconeogenesis. These observations, together with the reduction in the serum concentrations of gluconeogenic precursors in DNPI3K mice, suggest that a shortage of gluconeogenic precursors may prevent DNPI3K mice from increasing the fasting blood glucose level.
Discussion
Although in vitro studies have suggested that class I A PI 3-K plays an essential role in the metabolic actions of insulin (1, 2), targeted disruption of regulatory subunits of this enzyme resulted in apparently paradoxical phenotypes (11) (12) (13) (14) . We have now shown that systemic infusion of an adenoviral vector encoding a dominant negative mutant of PI 3-K (∆p85) resulted in, within 3 days, liver-specific expression of the mutant protein and prevented both the insulin-induced association of PI 3-K with IRS proteins and the insulin-induced phosphorylation of Akt in liver. Selective expression of ∆p85 in the liver also resulted in dyslipidemia and hyperinsulinemia and potentiated the increase in blood glucose concentration induced by oral glucose intake. These results provide direct evidence that the insulininduced activation of PI 3-K in the liver is required for metabolic actions of insulin in vivo.
An important characteristic of frank diabetes is fasting hyperglycemia, which is associated with an increase in hepatic glucose production (34) . Although the insulin-induced activation of PI 3-K was almost completely abolished in the liver of DNPI3K mice, the fasting blood glucose concentration of these animals was increased only slightly. Similarly, in mice with liver-specific knockout of the IR gene (LIRKO mice), in which insulin action in the liver should be virtually abolished, basal hepatic glucose production was not increased and the fasting blood glucose concentration was only slightly increased, despite an enhanced expression of gluconeogenic enzymes in the liver (35) . The abundance of gluconeogenic enzyme mRNAs in the liver was increased and the serum concentrations of gluconeogenic precursors were reduced in DNPI3K mice. In addition, the pyruvate-induced increase in blood glucose concentration, which was sensitive to a pharmacological inhibitor for gluconeogenesis, was enhanced in DNPI3K mice. These observations suggest that, in DNPI3K mice, and probably in LIRKO mice, a shortage of gluconeogenic substrates may prevent the development of marked fasting hyperglycemia. that mediated by PI3-K contributes to the metabolic features of DNPI3K mice. However, heterozygous knockout of the IRS-1 gene, which resulted in an approximately 50% decrease in the abundance of IRS-1 protein throughout the body, did not induce marked changes in metabolic parameters (40, 41) , suggesting that the metabolic characteristics of DNPI3K mice are dependent on the inhibition of PI 3-K signaling, not on suppression of other signaling pathways mediated by IRS-1. In summary, liver-specific expression of a dominant negative mutant of class I A PI 3-K resulted in insulin resistance, exaggerated hyperglycemia in response to oral glucose intake, and a reduced capacity of the liver to accumulate glucose 6-phosphate and glycogen. The mass of adipose tissue of DNPI3K mice in the fasted state was greater than that of control animals. The DNPI3K animals also exhibited impaired activation of PI 3-K in adipose tissue, probably as a result of the hyperinsulinemia induced by inhibition of insulin signaling in the liver. We believe our results provide the first evidence that PI 3-K is essential for metabolic regulation by insulin in living animals.
